IOVANCE BIOTHERAPEUTICS, INC. Files 8-K for Material Agreement
Ticker: IOVA · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.000041666, $350.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
IOVANCE BIOTHERAPEUTICS, INC. just filed an 8-K for a material definitive agreement. Big news coming.
AI Summary
On August 22, 2025, IOVANCE BIOTHERAPEUTICS, INC. entered into a material definitive agreement. The company, incorporated in Delaware with EIN 753254381, is involved in the Biological Products industry. This filing is a current report under the 1934 Act.
Why It Matters
This 8-K filing indicates a significant new agreement for IOVANCE BIOTHERAPEUTICS, INC., which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant new risks or opportunities that are not yet fully understood.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- August 22, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 753254381 (identifier) — I.R.S. Employer Identification No.
- 001-36860 (identifier) — Commission File Number
- Lion Biotechnologies, Inc. (company) — Former Company Name
- Genesis Biopharma, Inc (company) — Former Company Name
- FREIGHT MANAGEMENT CORP (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement filed by IOVANCE BIOTHERAPEUTICS, INC.?
The filing explicitly states 'Entry into a Material Definitive Agreement' as an item of information, but the specific details of the agreement are not provided in this excerpt.
When was this 8-K report filed?
The report was filed on August 22, 2025.
What is IOVANCE BIOTHERAPEUTICS, INC.'s primary business sector?
IOVANCE BIOTHERAPEUTICS, INC. is in the Biological Products sector, specifically SIC code 2836.
Has IOVANCE BIOTHERAPEUTICS, INC. undergone name changes in the past?
Yes, the company was formerly known as Lion Biotechnologies, Inc., Genesis Biopharma, Inc, and FREIGHT MANAGEMENT CORP.
What is the state of incorporation for IOVANCE BIOTHERAPEUTICS, INC.?
The company is incorporated in Delaware.
Filing Stats: 903 words · 4 min read · ~3 pages · Grade level 10 · Accepted 2025-08-22 17:18:10
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
- $350.0 million — Jefferies, acting as sales agent, up to $350.0 million of shares of the Company's common stock
Filing Documents
- tm2524060d1_8k.htm (8-K) — 31KB
- tm2524060d1_ex1-1.htm (EX-1.1) — 223KB
- tm2524060d1_ex5-1.htm (EX-5.1) — 8KB
- 0001104659-25-081953.txt ( ) — 486KB
- iova-20250822.xsd (EX-101.SCH) — 3KB
- iova-20250822_lab.xml (EX-101.LAB) — 33KB
- iova-20250822_pre.xml (EX-101.PRE) — 22KB
- tm2524060d1_8k_htm.xml (XML) — 4KB
01
Item 1.01. Entry Into a Material Definitive Agreement. On August 22, 2025, Iovance Biotherapeutics, Inc. (the " Company ") entered into an Amended and Restated Open Market Sale Agreement (the " Agreement ") with Jefferies LLC (" Jefferies ") with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $350.0 million of shares of the Company's common stock, par value $0.000041666 per share (the " Common Shares "). The issuance and sale, if any, of the Common Shares by the Company under the Agreement will be made pursuant to a prospectus supplement, dated August 22, 2025, to the Company's registration statement on Form S-3ASR, originally filed with the Securities and Exchange Commission on June 16, 2023, which became effective immediately upon filing. Pursuant to the Agreement, Jefferies may sell the Common Shares by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act of 1933, as amended (the " Securities Act "). Jefferies will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Common Shares from time to time, based upon instructions from the Company (including any price or size limits or other customary parameters or conditions the Company may impose). The Company will pay Jefferies a commission of up to 3.0% of the gross sales proceeds of any Common Shares sold through Jefferies under the Agreement. The Company is not obligated to make any sales of Common Shares under the Agreement. The offering of Common Shares pursuant to the Agreement will terminate upon the termination of the Agreement in accordance with its terms. The Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has agreed to indemnify Jefferies against certain liabilities, includ
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Amended and Restated Open Market Sale Agreement dated August 22, 2025, by and between Iovance Biotherapeutics, Inc. and Jefferies LLC. 5.1 Opinion of DLA Piper LLP (US). 23.1 Consent of DLA Piper LLP (US) (contained in Exhibit 5.1). 104 Cover Page Interactive Data File - the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 22, 2025 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel